Spontaneous Myocardial Infarction and Nitric Oxide Synthase

Trends in Cardiovascular Medicine

Volumn 18, Issue 8, 2008, Pages 275-279

  Tsutsui, Masato ^a   Nakata, Sei ^a   Shimokawa, Hiroaki ^b   Otsuji, Yutaka ^a   Yanagihara, Nobuyuki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; ENZYME ACTIVITY; GENE DELETION; HEART INFARCTION; HUMAN; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANIMALS; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RISK FACTORS; VASOCONSTRICTION;

EID: 63249126340     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2008.12.002     Document Type: Review

References (37)

1. Antman E.M., and Braunwald E. Acute myocardial infarction. In: Braunwald E. (Ed). Heart Disease (1997), W. B. Saunders company, Philadelphia 1184-1207
2. Antman E.M., and Braunwald E. ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Zipes D.P., Libby P., Bonow R.O., and Braunwald E. (Eds). Braunwald's Heart Disease (2005), Elsevier Saunders, Philadelphia 1141-1166
3. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90 (1992) 278-281
4. Braun A., Trigatti B.L., Post M.J., et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 90 (2002) 270-276
5. Bredt D.S., and Snyder S.H. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem 63 (1994) 175-195
6. Buxton I.L.O., Cheek D.J., Eckman D., et al. NG-nitro-l-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res 72 (1993) 387-395
7. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect, a Chinese concept for a worldwide pandemic. Swiss Med Wkly 136 (2006) 103-113
8. Cooke J.P. ADMA: its role in vascular disease. Vasc Med 10 Suppl 1 (2005) S11-S17
9. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 (2005) 2745-2749
10. Furchgott R.F. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 24 (1984) 175-197
11. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100 (1997) 2153-2157
12. Heim K.F., Thomas G., and Ramwell P.W. Effect of substituted arginine compounds on superoxide production in the rabbit aorta. J Pharmacol Exp Ther 257 (1991) 1130-1135
13. Huang A., Sun D., Shesely E.G., et al. Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am J Physiol Heart Circ Physiol 282 (2002) H429-H436
14. Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 30 (1990) 535-560
15. Kurioka S., Koshimura K., Murakami Y., et al. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J 47 (2000) 77-81
16. Laine P., Kaartinen M., Penttila A., et al. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99 (1999) 361-369
17. Lamping K.G., Nuno D.W., Shesely E.G., et al. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol 279 (2000) H1906-H1912
18. Luscher T.F., and Vanhoutte P.M. The endothelium: modulator of cardiovascular function (1990), CRC Press, Boca Raton, FL
19. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
20. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
21. Morishita T., Tsutsui M., Shimokawa H., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 102 (2005) 10616-10621
22. Moroi M., Zhang L., Yasuda T., et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 101 (1998) 1225-1232
23. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle?. Circulation 95 (1997) 1101-1103
24. Nakata S., Tsutsui M., Shimokawa H., et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117 (2008) 2211-2223
25. Node K., Kitakaze M., Yoshikawa H., et al. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 30 (1997) 405-408
26. Peterson D.A., Peterson D.C., Archer S., and Weir E.K. The nonspecificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun 187 (1992) 797-801
27. Piatti P., Di Mario C., Monti L.D., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108 (2003) 2074-2081
28. Sessa W.C. The nitric oxide synthase family of proteins. J Vasc Res 31 (1994) 131-143
29. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 31 (1999) 23-37
30. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
31. Suda O., Tsutsui M., Morishita T., et al. Long-term treatment with Nω-nitro-l-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 106 (2002) 1729-1735
32. Suda O., Tsutsui M., Morishita T., et al. Asymmetric dimethylarginine produces vascular lesion in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24 9 (2004) 1682-1688
33. Tanaka S., Yashiro A., Nakashima Y., et al. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol 20 (1997) 361-365
34. É÷-nitro-l-arginine benzyl ester, a potent irreversible inhibitor of endothelium dependent relaxation. Biochem Biophys Res Commun 179 (1991) 1677-1682
35. Tsutsui M. Neuronal nitric oxide synthase as a novel anti-atherogenic factor. J Atheroscler Thromb 11 (2004) 41-48
36. Tsutsui M., Shimokawa H., Morishita T., et al. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci 102 (2006) 147-154
37. Vanhoutte P.M., and Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 80 (1989) 1-9